Finding Consistency and Scalability in Allogeneic CAR-T Production

As the industry transitions from small-batch autologous processes to large-batch allogeneic ones, manufacturers need scalable systems that provide consistent performance to meet rigorous regulatory standards. In this article, we feature our partnership with Qasim Rafiq, a professor of cell and gene therapy bioprocessing at University College London (UCL) in the United Kingdom. This research focuses on developing, optimizing, and intensifying CAR-T processes in stirred tank bioreactors (STRs), with the goal of scaling up production.